Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: A population-based analysis

Linda Lee, Michael Crump, Sara Khor, Jeffrey S Hoch, Jin Luo, Karen Bremner, Murray Krahn, David C. Hodgson

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We conducted a multi-institutional population-based analysis of the survival and toxicity associated with the addition of rituximab to chemotherapy for patients with diffuse large B-cell lymphoma (DLBCL), including patients aged ≥80 years, who were excluded from published randomized trials. Using population-based registries in Ontario, we identified 4021 patients who received chemotherapy with or without rituximab (R-CHOP [rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone] or CHOP) for DLBCL between 1996 and 2007, including 397 patients aged ≥80 years. After propensity score matching, the overall survival (OS) and significant toxicities for R-CHOP and CHOP treatment groups were compared. R-CHOP was associated with a significant increase in 5-year OS compared to CHOP alone (62% vs. 54%; hazard of death = 0·78, P = 0·0004). Survival benefit was seen in all age groups, including those aged ≥80 years. Patients treated with rituximab did not have a significant increase in 1-year hospitalization rates for cardiac, pulmonary, gastrointestinal or neurological diagnoses compared to those treated with CHOP alone. The addition of rituximab to CHOP improves survival in the general population of patients with DLBCL and produces early survival benefit for very elderly patients, without any significant increase in the risk of serious toxicity.

Original languageEnglish (US)
Pages (from-to)481-488
Number of pages8
JournalBritish Journal of Haematology
Volume158
Issue number4
DOIs
StatePublished - Aug 2012
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Population
Survival
Drug Therapy
Propensity Score
Vincristine
Ontario
Survival Analysis
Prednisone
Rituximab
Doxorubicin
Cyclophosphamide
Registries
Hospitalization
Age Groups
Lung

Keywords

  • Diffuse large B-cell lymphoma
  • Elderly
  • Outcomes
  • Rituximab
  • Toxicity

ASJC Scopus subject areas

  • Hematology

Cite this

Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma : A population-based analysis. / Lee, Linda; Crump, Michael; Khor, Sara; Hoch, Jeffrey S; Luo, Jin; Bremner, Karen; Krahn, Murray; Hodgson, David C.

In: British Journal of Haematology, Vol. 158, No. 4, 08.2012, p. 481-488.

Research output: Contribution to journalArticle

Lee, Linda ; Crump, Michael ; Khor, Sara ; Hoch, Jeffrey S ; Luo, Jin ; Bremner, Karen ; Krahn, Murray ; Hodgson, David C. / Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma : A population-based analysis. In: British Journal of Haematology. 2012 ; Vol. 158, No. 4. pp. 481-488.
@article{56088570986f4bd4b382b79e81c2c8e4,
title = "Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: A population-based analysis",
abstract = "We conducted a multi-institutional population-based analysis of the survival and toxicity associated with the addition of rituximab to chemotherapy for patients with diffuse large B-cell lymphoma (DLBCL), including patients aged ≥80 years, who were excluded from published randomized trials. Using population-based registries in Ontario, we identified 4021 patients who received chemotherapy with or without rituximab (R-CHOP [rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone] or CHOP) for DLBCL between 1996 and 2007, including 397 patients aged ≥80 years. After propensity score matching, the overall survival (OS) and significant toxicities for R-CHOP and CHOP treatment groups were compared. R-CHOP was associated with a significant increase in 5-year OS compared to CHOP alone (62{\%} vs. 54{\%}; hazard of death = 0·78, P = 0·0004). Survival benefit was seen in all age groups, including those aged ≥80 years. Patients treated with rituximab did not have a significant increase in 1-year hospitalization rates for cardiac, pulmonary, gastrointestinal or neurological diagnoses compared to those treated with CHOP alone. The addition of rituximab to CHOP improves survival in the general population of patients with DLBCL and produces early survival benefit for very elderly patients, without any significant increase in the risk of serious toxicity.",
keywords = "Diffuse large B-cell lymphoma, Elderly, Outcomes, Rituximab, Toxicity",
author = "Linda Lee and Michael Crump and Sara Khor and Hoch, {Jeffrey S} and Jin Luo and Karen Bremner and Murray Krahn and Hodgson, {David C.}",
year = "2012",
month = "8",
doi = "10.1111/j.1365-2141.2012.09177.x",
language = "English (US)",
volume = "158",
pages = "481--488",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma

T2 - A population-based analysis

AU - Lee, Linda

AU - Crump, Michael

AU - Khor, Sara

AU - Hoch, Jeffrey S

AU - Luo, Jin

AU - Bremner, Karen

AU - Krahn, Murray

AU - Hodgson, David C.

PY - 2012/8

Y1 - 2012/8

N2 - We conducted a multi-institutional population-based analysis of the survival and toxicity associated with the addition of rituximab to chemotherapy for patients with diffuse large B-cell lymphoma (DLBCL), including patients aged ≥80 years, who were excluded from published randomized trials. Using population-based registries in Ontario, we identified 4021 patients who received chemotherapy with or without rituximab (R-CHOP [rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone] or CHOP) for DLBCL between 1996 and 2007, including 397 patients aged ≥80 years. After propensity score matching, the overall survival (OS) and significant toxicities for R-CHOP and CHOP treatment groups were compared. R-CHOP was associated with a significant increase in 5-year OS compared to CHOP alone (62% vs. 54%; hazard of death = 0·78, P = 0·0004). Survival benefit was seen in all age groups, including those aged ≥80 years. Patients treated with rituximab did not have a significant increase in 1-year hospitalization rates for cardiac, pulmonary, gastrointestinal or neurological diagnoses compared to those treated with CHOP alone. The addition of rituximab to CHOP improves survival in the general population of patients with DLBCL and produces early survival benefit for very elderly patients, without any significant increase in the risk of serious toxicity.

AB - We conducted a multi-institutional population-based analysis of the survival and toxicity associated with the addition of rituximab to chemotherapy for patients with diffuse large B-cell lymphoma (DLBCL), including patients aged ≥80 years, who were excluded from published randomized trials. Using population-based registries in Ontario, we identified 4021 patients who received chemotherapy with or without rituximab (R-CHOP [rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone] or CHOP) for DLBCL between 1996 and 2007, including 397 patients aged ≥80 years. After propensity score matching, the overall survival (OS) and significant toxicities for R-CHOP and CHOP treatment groups were compared. R-CHOP was associated with a significant increase in 5-year OS compared to CHOP alone (62% vs. 54%; hazard of death = 0·78, P = 0·0004). Survival benefit was seen in all age groups, including those aged ≥80 years. Patients treated with rituximab did not have a significant increase in 1-year hospitalization rates for cardiac, pulmonary, gastrointestinal or neurological diagnoses compared to those treated with CHOP alone. The addition of rituximab to CHOP improves survival in the general population of patients with DLBCL and produces early survival benefit for very elderly patients, without any significant increase in the risk of serious toxicity.

KW - Diffuse large B-cell lymphoma

KW - Elderly

KW - Outcomes

KW - Rituximab

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84864297051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864297051&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2012.09177.x

DO - 10.1111/j.1365-2141.2012.09177.x

M3 - Article

C2 - 22671571

AN - SCOPUS:84864297051

VL - 158

SP - 481

EP - 488

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -